Key facts
- Topos Bio’s last known valuation is $48.5M (Jan 2026).
- It has raised $11.1M across 1 recorded rounds; the latest was Early Stage VC ($9.0M) in Dec 2024.
- Notable investors include Boldstart Ventures, Threshold Ventures, Dara Khosrowshahi, Naveen Rao, Neo (Consulting Services (B2B)).
- Topos Bio has filed 1 Form D with the SEC, most recently Jan 2025 ($9.0M sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Topos Bio
Funding rounds
1 roundsAbout Topos Bio
Operator of a biotechnology company intended for AI-driven drug discovery for intrinsically disordered proteins. The company's models generate large-scale ensembles that capture protein dynamics, identify transient binding opportunities within these fluctuating structures, and apply generative chemistry to design small molecules tailored to modulate disordered regions, enabling people to help get cures for their diseases.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2024
- Website
- toposbio.ai/
- Ownership
- Privately Held (backing)
Topos Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Topos Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Topos Bio in its N-PORT filings yet. We sweep new filings monthly.